Abstract:Abstract Background and aims The modulation of serum lipids, in particular of the low-density lipoprotein cholesterol (LDL-C), by statins varies between individuals. The mechanisms regulating this interindividual variation are only poorly understood. Here, we investigated the relation between the gut microbiome and the regulatory properties of atorvastatin on the serum lipidome using mice with depleted gut microbiome. Methods Over a period of 6 weeks, mice (C57BL/6) with either an intact (conventional mice, CONV, n=24) or antibiotic-based depleted gut microbiome (antibiotic treated mice, ABS, n=16) were put on standard chow diet (SCD) or high fat diet (HFD), respectively. During the last 4 weeks of treatment atorvastatin (Ator, 10mg/kg body weight/day) or control vehicle was administered via daily oral gavage. Blood lipids (total cholesterol, VLDL, LDL-C, HDL-C) and serum sphingolipids were compared among the groups. The expressions of hepatic and intestinal genes involved in cholesterol metabolism were analyzed by qRT-PCR. Alterations in the gut microbiota profile of mice with intact gut microbiome were examined using 16S RNA qRT-PCR. Results In CONV mice, HFD led to significantly increased blood LDL-C levels as compared with SCD (HFD: 36.8±1.4 mg/dl vs. SCD: 22.0±1.8 mg/dl; P<0.01). In CONV mice atorvastatin treatment significantly reduced blood LDL-C levels after HFD, whereas in ABS mice the LDL-C lowering effect of atorvastatin was markedly attenuated (CONV+HFD+Ator: 31.0±1.8 mg/dl vs. ABS+HFD+Ator: 46.4±3 mg/dl; P<0.01). A significant reduction in the abundance of several plasma lipids, in particular sphingolipids and glycerophospholipids upon atorvastatin treatment was observed in CONV mice, but not in ABS mice. The expressions of distinct hepatic and intestinal cholesterol-regulating genes (ldlr, srebp2, pcsk9 and npc1l1) upon atorvastatin treatment were significantly altered in gut microbiota depleted mice. In response to HFD a decrease in the relative abundance of the bacterial phyla Bacteroides and an increase in the relative abundance of Firmicutes was observed. The altered ratio between Bacteroides and Firmicutes in HFD fed mice was partly reversed upon atorvastatin treatment. Conclusions Our findings indicate a crucial role of the gut microbiome for the regulatory properties of atorvastatin on the serum lipidome and, in turn, support a critical impact of atorvastatin on the gut microbial composition. The results provide novel insights into potential microbiota related mechanisms underlying interindividual variation in modulation of the serum lipidome by statins, given interindividual differences in microbiome composition and function. Funding Acknowledgement Type of funding source: Foundation. Main funding source(s): German Heart Research Foundation

Impact of the gut microbiome on the atorvastatin-dependent modulation of the serum lipidome

Impact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids

The Intestinal Effect of Atorvastatin: Akkermansia Muciniphila and Barrier Function

Gut Microbiota Modulation Attenuated the Hypolipidemic Effect of Simvastatin in High-Fat/Cholesterol-Diet Fed Mice

An In Vitro Evaluation Of The Effects Of Different Statins On The Structure And Function Of Human Gut Bacterial Community

Alterations in Gut Microbiota by Statin Therapy and Possible Intermediate Effects on Hyperglycemia and Hyperlipidemia

Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E−/− mice

Antibiotic-induced gut microbiota depletion exacerbates host hypercholesterolemia

Molecular Characterization Of Gut Microbiota In High-Lipid Diet-Induced Hyperlipidemic Rats Treated With Simvastatin

Targets of statins intervention in LDL-C metabolism: Gut microbiota

Simvastatin induces human gut bacterial cell surface genes

The Novel Interplay Between Commensal Gut Bacteria and Metabolites in Diet-Induced Hyperlipidemic Rats Treated with Simvastatin

An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a)

Role of gut microbiota and metabolomics in the lipid-lowering efficacy of statins among Chinese patients with coronary heart disease and hypercholesterolemia

Effects of Atorvastatin on Bile Acid Metabolism in High-Fat Diet-Fed ApoE-/- Mice

A gut feeling of statin

Both gut microbiota and cytokines act to atherosclerosis in ApoE -/- mice

The gut microbiota is associated with clinical response to statin treatment in patients with coronary artery disease

The interplay between dietary fatty acids and gut microbiota influences host metabolism and hepatic steatosis

The gut microbiome dysbiosis is recovered by restoring a normal diet in hypercholesterolemic pigs

A two-sample Mendelian randomization study reveals the causal effects of statin medication on gut microbiota abundance in the European population